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ABSTRACT
Introduction: Multiple significant, potentially
practice changing clinical trials in cardiology
have been conducted and subsequently
presented throughout the past year.
Methods: In this paper, the authors have
reviewed and contextualized significant
cardiovascular clinical trials presented at major
international conferences of 2015 including
American College of Cardiology, European
Association for Percutaneous Cardiovascular
Interventions, American Diabetes Association,
European Society of Cardiology, Transcatheter
Cardiovascular Therapeutics, Heart Rhythm
Congress, and the American Heart Association
Scientific Sessions.
Results: The authors describe new trial data for
heart failure (including eplerenone, finerenone,
patiromer, sacubitril/valsartan, the beta 3
agonist mirabegron, sitagliptin, empagliflozin,
alginate-hydrogel LV epicardial implant),
anticoagulation (idarucizumab and
andexanet alfa reversal agents, adherence
programmes, practice in ablation),
transcatheter aortic valve replacement
(long-term data, valve-in-valve use, the
TriGuard embolic deflecting device), patent
foramen ovale closure, cardiovascular
prevention (PCSK9 inhibitors, hypertension
treatment) and antiplatelets strategies
(extended duration therapy with clopidogrel
or ticagrelor). Trial data are also described for
contemporary technologies including the
Biofreedom polymer-free drug coated stent,
bioabsorbable stents, PCI strategies, left main
treatment, atrial fibrillation ablation
techniques, leadless pacemakers and the role
of coronary computed tomographic
angiography.
Conclusions: This paper summarizes and
contextualizes multiple pertinent 2015 clinical
trials and will be of interest to both clinicians
and cardiology researchers.
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INTRODUCTION
Over the past year, multiple noteworthy trials
with the potential to evolve current clinical
practice and guidelines have been presented at
international meetings including the American
College of Cardiology (ACC, San Diego, USA,
March 2015), European Association for
Percutaneous Cardiovascular Interventions
(EuroPCR, Paris, France, May 2015), American
Diabetes Association (ADA, MA, USA, June
2015), European Society of Cardiology (ESC,
London, UK, August 2015), Transcatheter
Cardiovascular Therapeutics (TCT, San
Francisco, USA, October 2015), Heart Rhythm
Congress (HRC, Birmingham, UK, October
2015), and the American Heart Association
Scientific Sessions (AHA, Florida, USA,
November 2015). In this paper the authors
describe new clinical data placed in the
context of acute coronary syndrome (ACS),
interventional cardiology, heart failure, atrial
fibrillation, electrophysiology, and coronary
prevention.
METHODS
The results of major clinical trials in cardiology
presented at major conferences in 2015 were
reviewed by the authors. Search terms included
‘‘acute coronary syndrome’’, ‘‘atrial fibrillation’’,
‘‘coronary prevention’’, ‘‘electrophysiology’’,
‘‘heart failure’’, and ‘‘interventional
cardiology’’. Trials were selected based on
relevance to the cardiovascular (CV)
community, the potential to change clinical
practice, and the potential to guide further
phase 3 research. This article is based on
previously conducted studies and does not
involve any new studies of human or animal
subjects performed by any of the authors.
HEART FAILURE
Advances in heart failure (HF) have featured
prominently in many 2015 conferences with
particular focus on addressing the side effects of
currently used drug classes. Mineralocorticoid
antagonists (MRAs) have a class 1A
recommendation for reduction in mortality
and hospitalization in patients with heart
failure with reduced ejection fraction (EF).
However, this drug class is typically
under-prescribed due to concerns regarding
hyperkalemia and renal impairment in
high-risk patients. Finerenone is a novel
non-steroidal MRA with greater receptor
selectivity than spironolactone and better
receptor affinity than eplerenone in vitro
[1, 2], which may have the potential to reduce
side effects of hyperkalemia and renal
impairment [1]. The ARTS-HF
(mineralocorticoid Receptor antagonist
Tolerability Study-Heart Failure) double-blind
controlled phase 2b trial (ClinicalTrials.gov
#NCT01807221) randomized 1060 patients
with heart failure (HF), type 2 diabetes
mellitus (T2DM) ± chronic kidney disease
(CKD) to finerenone (titrated from one of five
doses from 2.5 to 20 mg) or eplerenone
(titrating from 25 to 50 mg) [1, 2]. Although
the proportion of patients with a relative
decrease of 30% in 90-day NT-proBNP
(primary endpoint) was similar in all groups,
the measurement of NT-proBNP to predict
clinical outcome is not well established, and
the subgroup of patients receiving finerenone
10–20 mg showed a 44% reduction the
secondary clinical composite endpoint of
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90-day all-cause death, CV death,
hospitalization, or emergency presentation for
worsening chronic HF [1, 2]. Finerenone
10–20 mg appeared better tolerated than
eplerenone with a smaller increase in
potassium (0.119 vs. 0.262 mmol/l; p = 0.016)
and lower incidence of estimated glomerular
filtration rate (eGFR) decrease[40% (4.2% vs.
9.4%) [1, 2]. A phase 3 trial has been
announced.
Hyperkalemia is a common concern in HF
patients using renin-angiotensin-aldosterone
(RAAS) inhibitors [3]. In a previous trial,
OPAL-HK (ClinicalTrials.gov #NCT01810939),
investigators showed a short-term sustained
decrease in potassium in patients with HF
taking the potassium binder patiromer with
RAAS inhibitors [4]. The phase 2 AMETHYST DN
trial (ClinicalTrials.gov #NCT01371747)
assigned 304 patients with CKD, hypertension
(HTN), T2DM, serum potassium above 5 mEq/l
and who were taking RAAS inhibitors to
patiromer (starting dose stratified by baseline
potassium) [5]. Patiromer reduced potassium
within days and maintained levels\5 mEq/l in
patients with HF (n = 105) or without HF
(n = 199) for up to 1 year (p\0.001). In total,
74% of the HF subgroup completed the trial, 7%
withdrew consent, and a further 7% had adverse
effects such as diarrhea, hypokalemia, and
hypomagnesemia [5]. Further studies are
planned to assess if improved control of
hyperkalemia will translate into survival
benefit [5].
Renal dysfunction is another common issue
with RAAS inhibitors. A combination of the
neprilysin inhibitor sacubitril and the
angiotensin receptor blocker valsartan
(LCZ696) was previously shown to decrease
the primary endpoint of CV death or HF
hospitalization, CV death, and a reduction in
all-cause mortality compared with enalapril in
the 2014 PARADIGM-HF study (prospective
comparison of ARNI with ACEI to Determine
Impact on Global Mortality and Morbidity in
HF) (ClinicalTrials.gov #NCT01035255) [3, 6].
The renal tolerability of sacubitril/valsartan was
presented at the ESC Congress 2015 [7]. Over a
48-month period, eGFR decreased by 0.14 ml/
min/1.73 m2 in the enalapril group and
0.11 ml/min/1.73 m2 in the sacubitril/valsartan
groups, respectively (p = 0.001) [7]. Although, it
should be noted that patients with an acute
initial decline in eGFR were excluded from the
PARADIGM-HF study [7], CV death or HF
hospitalization was reduced similarly in the
CKD group (36% of the study population)
compared to those without baseline CKD (HR
0.790 vs. 0.799; p = 0.90 for interaction), [7]
suggesting a favorable cardiorenal profile [7].
The value of MRA treatment in mild heart
failure has already been established by the prior
EMPHASIS-HF study (Eplerenone in Mild
Patients Hospitalization and Survival Study in
Heart Failure) (ClinicalTrials.gov
#NCT00232180) in which eplerenone reduced
the rate of CV death or HF hospitalization
(18.3% vs. 25.9%; HR 0.63) among patients with
New York Heart Association (NYHA) class II
symptoms and an EF B35% [8]. The potential
for extension of MRA use to patients without
previously diagnosed HF was investigated by
the open label ALBATROSS (Aldosterone Lethal
Effects Blockade in Acute Myocardial Infarction
Treated With or Without Reperfusion to
Improve Outcome and Survival at Six Months’
Follow-Up) (ClinicalTrials.gov #NCT01059136)
trial in which 1600 patients without known HF
were randomized to spironolactone or control
within 72 h of MI (myocardial infarction) [9].
Although there was a suggestion of benefit in
the ST elevation subgroup (1229), overall, no
significant difference was found in the primary
composite endpoint of death, resuscitated
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cardiac death, ventricular fibrillation/
ventricular tachycardia, HF, or indication for
implantable cardiac defibrillator at 6 months
[HR 0.97; 95% confidence interval (CI)
0.73–1.28; p = 0.81] [9] and thus results do not
justify extension of MRA use at present.
Patients receiving some cancer
chemotherapy treatments may be at risk of
developing HF. It is unclear if this risk can be
reduced by use of cardioprotective drugs. The
Prevention of Cardiac Dysfunction During
Adjuvant Cancer Therapy (PRADA) trial
(ClinicalTrials.gov #NCT01434134)
randomized 126 breast cancer patients with a
baseline EF of [50% being treated with
anthracycline ± trastuzumab and radiation to
a protective strategy of candesartan or
metoprolol vs. placebo [10]. Patients receiving
candesartan had a significantly smaller decline
in EF from baseline vs. placebo (0.8% vs. 2.6%;
p = 0.026) [10]. No significant benefit was
demonstrated for metoprolol [10]. Although
small in size, this study suggests potential
benefit from candesartan therapy in this
patient group.
Previous studies have yielded conflicting
conclusions regarding the mortality effect of
digoxin among patients with congestive heart
failure (CHF) [11, 12]. Madelaire et al. thus
conducted an observational study using a
Danish nationwide registry of patients
discharged from hospital with both HF and
atrial fibrillation (AF), excluding those receiving
antiarrhythmic therapy (e.g., amiodarone),
those who died within 30 days of discharge,
and those not taking a vitamin-K antagonist,
then matching the 8078 digoxin-treated
patients with 8078 control patients, based on
age, sex, comorbidities, CHA2DS2VASc score,
medication, and heart-failure severity [13]. The
risk of death was reduced [hazard ratio (HR)
0.92; (CI 95% 0.86–0.98) and risk of
readmission increased HR 1.07; 95% CI
1.01–1.12] with digoxin users [13]. When
death was considered as a competing risk, the
collective incidences of readmission were
similar at 64.9% in digoxin users and 64.4% in
non-users [13]. The authors concluded that in
digoxin-naive patients with AF, digoxin use was
associated with a slightly reduced risk of death
[13].
A novel heart failure strategy may be
attenuation of myocyte sodium overload by
beta 3 agonists. In the Beta 3 Agonists
Treatment in HF (BEAT-HF) trial
(ClinicalTrials.gov #NCT01876433) [14, 15], 70
patients with HF were randomized to the beta 3
agonist Mirabegron or placebo for 6 months
[14, 15]. While Mirabegron was not associated
with improvement in patients with a baseline EF
[40% (mean difference 0.4%; 95% CI -3.5 to
3.8; p = 0.82) an exploratory analysis of patients
with a baseline EF B40% noted a 5.5% increase
in EF (95% CI 0.6–10.4; p\0.03) [14, 15].
Further studies are thus planned in patients
with severe heart failure [15].
Since some diabetes therapies including
some thiazolidinediones and some DPP-4
inhibitors have been associated with an
increased risk of HF events, new diabetes
therapies require rigorous evaluation of CV
safety. TECOS (Trial Evaluating Cardiovascular
Outcomes with Sitagliptin) (ClinicalTrials.gov
#NCT00790205) randomized 14,671 patients
with diabetics and CV disease (history of
major coronary artery disease, ischemic
cerebrovascular disease, or atherosclerotic
peripheral arterial disease) to sitagliptin vs.
placebo [16]. At 3 years, there was no
difference in the primary endpoint of CV
death, non-fatal MI, non-fatal stroke, or
hospitalization for unstable angina for with
sitagliptin vs. placebo (11.4% vs. 11.6%;
p\0.001 for noninferiority) [16], no difference
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in total HF hospitalization events (345 vs. 347
placebo; p = 0.996) [16, 17] and in the subgroup
of patients with HF at baseline, no significant
difference in hospitalization for HF (7.4% vs.
7.0% HR 1.03; 95% CI 0.77–1.36; p = 0.86) [17].
Thus, in contrast to some previous gliptin data,
no signal to increased HF was seen, which could
reflect differences in clinical or patient factors,
or a potential intrinsic pharmacologic
difference among the DPP-4 inhibitors [18, 19].
The sodium glucose cotransporter 2 (SGLT2)
is responsible for 90% of reabsorption of urinary
glucose. Inhibition of SGLT2 has been found to
significantly reduce HbA1c, weight, and blood
pressure and may augment natriuresis [20, 21].
EMPA-REG OUTCOME (ClinicalTrials.gov
#NCT01131676) randomized 7020 patients
with T2DM and at high CV risk to the highly
selective SGLT2 inhibitor empagliflozin (10 or
25 mg) or placebo [20, 21]. Patients with eGFR
\30 ml/min/1.73 m2 were excluded. HF was
not an exclusion although most patients did
not have HF at baseline [20, 21]. Empagliflozin
was associated with a 14% reduction in the
primary composite outcome of CV death,
nonfatal MI, or nonfatal stroke (10.5% vs.
12.1%; HR 0.86; 95% CI 0.74–0.99; p = 0.0382
for superiority) largely driven by a 38%
reduction in CV death (3.67% vs. 5.87%; HR
0.62; 95% CI 0.49–0.77; p\0.0001) [20].
Empagliflozin was also associated with a 34%
reduction in HF hospitalization or CV death
(HR 0.66; 95% CI 0.55–0.79; p\0.0001) and
39% reduction in hospitalization for, or death
from, HF (HR 0.61; 95% CI 0.47–0.79;
p = 0.0002) [20]. Although these findings were
consistent in both patients with and without HF
at baseline, numerically there were very few
events in patients without baseline HF [20].
Multiple non-pharmacological HF strategies
were presented during 2015. AUGMENT-HF
(ClinicalTrials.gov #NCT01311791) assessed
the clinical impact of an alginate-hydrogel LV
epicardial implant placed during open
thoracotomy (Fig. 1), designed to serve as a LV
scaffold with the aim of reducing adverse
remodeling [22]. Of 78 patients with advanced
HF and LEF B35% randomized to the alginate
implant or placebo, 58 patients completed
1-year follow-up [22]. Peak VO2 was
significantly improved in the alginate group
(mean increase 2.10 ml/kg/min; 95% CI
0.96–3.24; p\0.001) with significantly
improved NYHA status and 6-min walk test
distance (p\0.001) [22]. While a note of
caution is needed given nine (22.5%) deaths
in the alginate vs. four (10.5%) deaths in the
control group (p = ns), the trial was not
powered to assess mortality and further
clinical trials are planned for this novel
approach [22].
Fig. 1 AUGMENT-HF Alginate-hydrogel LV epicardial
implantation at the mid-ventricular level (a) with equal
spacing from the antero-septal groove and ending at the
postero-septal groove (b). Reproduced with permission
from Anker, Coats & Christian, et al. A prospective
comparison of alginatehydrogel with standard medical
therapy to determine the impact on functional capacity
and clinical outcomes in patients with advanced heart
failure (AUGMENTHF trial). Eur Heart J. 2015, 36:
2297–2309
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Large infarcts are associated with
degradation of extracellular matrix. Previous
preclinical studies and a small human pilot trial
have shown that Bioabsorbable Cardiac Matrix
(BCM) IK-5001 (an aqueous mixture of sodium
alginate and calcium gluconate) when given as
an intracoronary bolus can flow to the
extracellular space where it forms a flexible
hydrogel matrix, thickening the infarct zone,
reducing LV wall stress, and potentially
reducing adverse remodeling. Once the infarct
heals, BCM gradually dissipates and is renally
excreted. In PRESERVATION I
(ClinicalTrials.gov #NCT01226563), 303
patients with moderate to large STEMIs (EF
\35% or MI size [20%) were randomized to
intracoronary injection of 4 ml BCM (n = 201)
vs. saline control (n = 102) 2–5 days after their
primary PCI [23]. Injection of BCM was not
associated with any difference vs. saline in the
primary endpoint (change in LV end diastolic
volume index (LVEDVI) from baseline to
6 months), or in secondary endpoints
including 6-min walk test, NYHA grade, CV
hospitalization, or death. BCM injection was
associated with five temporary angiographic
occlusions vs. one with saline [23]. The
disappointing discrepancy between pre-clinical
data and PRESERVATION I findings may have
been related to microvascular obstruction and
edema preventing entry of BCM into the
myocardium [23].
HF may be complicated by sleep-disordered
breathing and early treatment may improve
outcomes. Seventy patients with acute HF
diagnosed with sleep apnea by overnight
polysomnography within 4 weeks of discharge
were treated with continuous positive airway
pressure (CPAP) treatment [24]. Of these, 37
(53%) met the definition of good compliance
with the CPAP device [24]. Patients with good
CPAP compliance showed a significant decrease
in 6-month readmission rates after therapy
compared with the 6-month readmission rates
pre-therapy (mean ± SE: -1.5 ± 0.2 events;
p\0.0001) [24].
Better effectiveness after transition–heart
failure (BEAT HF) (ClinicalTrials.gov
#NCT01360203) assessed care transition
intervention involving pre-discharge
education, regular scheduled telephone
coaching, and telemonitoring of weight, blood
pressure, heart rate, and symptoms in HF
patients [25]. Overall, there was no significant
effect on 30- and 180-day readmission (50.8%
vs. 49.2%, HR 1.03; 95% CI 0.88–1.20; p = 0.74)
or 180-day mortality [25]. However, in post hoc
analysis, adherence rates with the telephone
call and monitoring schedules was noted to be
variable. Patients with good telephone call
adherence ([50% calls completed) had lower
180-day mortality compared to non-adherent
patients (8.3% vs. 26%; p B 0.001) [25, 26].
Patients with good remote monitoring
adherence ([50% days) had lower 180-day
mortality (6.6% vs. 21.4%; p B 0.001) and
lower 180-day readmission rates (41.3% vs.
61.1%; p B 0.001) [25, 26]. While good
adherence to a telephone and telemonitoring
program appears to be of clinical benefit, as this




Until recently, the absence of a specific reversal
agent for non-vitamin K antagonist oral
anticoagulants (NOACs) has been seen as a
limitation. In late 2015, the first specific
reversal agent—idarucizumab—was approved
for reversal of the direct thrombin inhibitor
dabigatran [27]. Approval was based on interim
results of REVERSE-AD (ClinicalTrials.gov
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#NCT02104947) [28, 29] in 90 patients—51 with
serious bleeding (group A) and 39 requiring an
urgent procedure (group B). The anticoagulant
effects of dabigatran were rapidly (within
minutes) and completely reversed in 88 to 98%
of the patients who had had elevated clotting
times at baseline [29]. Unbound dabigatran
concentration at 24 h remained below 20 ng/ml
in 79% of patients. One thrombotic event
occurred within 72 h of idarucizumab in a
patient who had not received anticoagulant
re-initiation [29].
Factor Xa oral anticoagulants do not yet
have an approved reversal agent but
andexanet alfa—a recombinant engineered
version of human factor Xa with the ability to
bind factor Xa inhibitors—has been tested in
healthy older (aged 50–75) volunteers receiving
apixaban 5 mg twice daily or rivaroxaban 20 mg
once daily [30]. In apixaban participants,
andexanet alfa reduced anti-Xa activity by
94% (vs. 21% receiving placebo; p\0.001) and
thrombin generation was fully restored in 100%
(vs. 11% receiving placebo; p\0.001) within 2
to 5 min [30]. Among the rivaroxaban
participants, andexanet alfa reduced
anti-factor Xa activity by 92% (vs. 18%
receiving placebo) and thrombin generation
was fully restored in 96% (vs. 7% receiving
placebo; p\0.001) [30]. These effects were
sustained when andexanet was administered as
a bolus plus an infusion [30]. A phase IIIb/IV
trial is now recruiting patients with active
bleeding, treated with andexanet.
Balancing antithrombotic efficacy with
bleeding safety remains a clinical challenge.
REGULATE-PCI (ClinicalTrials.gov
#NCT01848106), randomized patients
undergoing PCI to the novel anti IXa
anticoagulant pegnivacogin (n = 1616) prior to
PCI with administration of the specific reversal
agent anivamersen at the end of the PCI, or to
bivalirudin (n = 1616) (standard bolus, plus
infusion for the duration of the PCI) [31]. The
trial was halted early as 10/1605 (0.6%) patients
had severe allergic reactions with the novel
regimen (including one fatality) compared to
one severe allergic reaction with bivalirudin and
had higher rates of bleeding (p = 0.002) [31].
However, the primary efficacy outcomes were
similar between the two groups, thus suggesting
that factor IXa could be a potential target if the
allergy issues could be addressed [31].
The Assessment of an Education and
Guidance Programme for Eliquis Adherence in
Non-Valvular Atrial Fibrillation (AEGEAN)
(ClinicalTrials.gov #NCT01884350) study
assessed the impact of an educational program
on adherence to apixaban for stroke prevention
in AF [32]. Adherence and persistence were
measured by an electronic monitoring device,
with non-adherence defined as a 24-h period
where two tablets were missed and
non-persistence a 30-day period of
discontinuation [32]. Adherence was 88.51%
for standard care and 88.34% for the
educational programme (p = 0.89) at week 24
[32]. Persistence at 24 weeks was 90.5% with
standard care and 91.1% with an educational
programme (p = 0.7) [32]. The authors
concluded there was no additional value
found so far with an educational programme
in the first 6 months of treatment. Long-term
adherence will be evaluated in a follow-up study
[32].
STRUCTURAL INTERVENTION
Currently, transcatheter aortic valve
replacement (TAVR) is indicated principally in
patients at high surgical risk. In the Nordic
Aortic Valve Intervention Trial (NOTION)
(ClinicalTrials.gov #NCT01057173), 280
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patients with severe aortic stenosis, an age over
70 but otherwise deemed low risk by the STS
(Society of Thoracic Surgeons) score (81% with a
score \4), and deemed suitable for either
procedure at a multidisciplinary conference,
were randomized to TAVR (Corevalve
Medtronic n = 145) or surgical aortic valve
replacement (SAVR n = 135) [33]. TAVR
compared with SAVR was associated with a
similar incidence in the primary endpoint of
composite death, stroke, or MI (13.1% vs.
16.3%, p = 0.43.), less major bleeding (11.3%
vs. 20.9% p = 0.03), less cardiogenic shock
(10.4% vs. 4.2% (p = 0.05), less acute kidney
injury (0.7% vs. 6.7% p = 0.01) and less
new/worsening AF at 1 year (21.2% vs. 59.4%;
p\0.001) although a higher incidence of
pacemaker requirement (38% vs. 2.4%;
p\0.001) and higher incidence of moderate to
severe aortic regurgitation at 1 year (15.7% vs.
0.9%; p\0.001) [33]. Echocardiography rather
than computed tomography (CT) was routinely
used for pre-procedure measurements, and low
TAVR placement was felt to contribute to
conduction abnormalities [33]. Although
underpowered, NOTION suggests TAVR may
be a reasonable alternative to surgical
intervention even in low-risk patients [33].
Neurological defects can be an important
complication of TAVR. DEFLECT 3
(ClinicalTrials.gov #NCT02070731) was a small
(n = 85) randomized trial investigating the use
of the TriGuard embolic deflecting device vs.
control in patients undergoing TAVR [34].
Complete three-vessel cerebral coverage was
achieved in 88.9% of patients assigned to
TriGuard [34]. No significant difference in
MACCE (major adverse cardiac or
cerebrovascular events) defined as death,
stroke, life-threatening or disabling bleeding,
acute kidney injury, or major vascular
complications was noted (TriGuard 21.7 vs.
control 30.8% subjects p = 0.34) [34].
However, patients with full three-vessel
coverage had greater freedom from new brain
lesions on magnetic resonance imaging (3.1%
vs. 15.4%) (Fig. 2), fewer new neurological
deficits (National Institutes of Health Stroke
Scale 3.1% vs. 15.4%), and a greater than
twofold increase in cognitive recovery at
30 days (assessed by Montreal Cognitive
Assessment scores) [34].
The PARTNER II (Placement of AoRTic
TraNscathetER Valves) trial (ClinicalTrials.gov
#NCT01314313) evaluated use of valve-in-valve
TAVR using the Edwards SAPIEN XT among 197
patients with severe aortic stenosis or
regurgitation, a previous surgical bioprosthetic
aortic valve and high operative risk [35].
Patients had to be suitable for 23-mm or
26-mm valve and patients with surgical valves
\21 mm were excluded [35]. At 1 year, the
primary endpoint of all-cause mortality was
13.4%, cardiac mortality was 8.9%, stroke rate
was 3.7%, and rehospitalization rate was 11.8%
[35]. Peri-procedural major bleeding occurred in
14.8% and acute kidney injury in 8.2% [35].
Significant clinical benefit compared with
baseline was noted for NYHA status, 6-min
walk test, and quality of life [35]. Although
non-randomized and sizing issues restrict the
applicable population, PARTNER II suggests
SAPIEN XT is a potential alternative to
CoreValve for valve-in-valve procedures [35].
In contrast to aortic valve disease,
conventional surgery remains the primary
treatment for mitral regurgitation in most
patients. The optimal surgical approach can be
hotly debated. Two-year results of a randomized
trial (ClinicalTrials.gov #NCT00807040)
comparing surgical mitral-valve repair with
surgical mitral-valve replacement in 251
patients with severe ischemic mitral
regurgitation were presented at AHA 2015 [36].
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There was no significant difference in mean left
ventricular end-systolic volume index at 2 years
(52.6 vs. 60.6 ml/m2) for repair vs. replacement,
and no difference in 2-year mortality (19.0% vs.
23.2% HR 0.79; 95% CI 0.46–1.35; p = 0.39)
[36]. However, repair was associated with a
higher rate of moderate or severe mitral
regurgitation (58.8% vs. 3.8%; p\0.001),
serious adverse events related to HF (p = 0.05)
and CV readmissions (p = 0.01) [36].
Ten-year data from the RESPECT trial,
investigating the Amplatzer PFO (patent
foramen ovale) (St Jude Medical)
(ClinicalTrials.gov #NCT00465270) in
preventing recurrent stroke in patients with
previous cryptogenic ischemic stroke (n = 499)
vs. guideline-directed therapy (n = 481) were
presented at TCT 2015 [37]. PFO closure was not
associated with significant reduction in
all-cause strokes in the overall
intention-to-treat analysis (18 vs. 24; p = 0.16)
but was associated with a significant reduction
in cryptogenic stroke (10 vs. 19; HR 0.46;
p = 0.042) [37]. In patients \60 years, PFO
closure was associated with a 52% reduction in
all-cause stroke (p = 0.035) [37] and in those
with atrial septal aneurysmal or substantial
shunts, PFO closure was associated with a 75%
reduction in all-cause stroke (p = 0.007) [37].
There was no intra-procedure stroke, no device
embolization, no device thrombosis, no device
erosion, a very low rate of major vascular
complications (0.9%) and device explants
(0.4%) [37]. RESPECT thus supports PFO
closure in selected patients.
ATHEROSCLEROSIS
Despite use of high-dose statin and ezetimibe,
patients with elevated LDL cholesterol can
remain at elevated CV risk. Proprotein
convertase subtilisin-kexin type 9 (PCSK9)
Fig. 2 DEFLECT III (a)% patients with complete freedom
from ischemic brain lesions in the intention-to-treat and
per-treatment analysis populations. Error bars represent 95%
conﬁdence intervals. b Per-subject median single and
maximum lesion volumes in the intention-to-treat and
per-treatment analysis populations. Error bars represent the
interquartile range. c Proportion of subjects experiencing a
total lesion volume by diffusion-weighted magnetic reso-
nance imaging in the given size range. Reproduced with
permission from Lansky, Schofer and Tchetche, et al. A
prospective randomized evaluation of the TriGuard HDH
embolic DEFLECTion device during transcatheter aortic
valve implantation: results from the DEFLECT III trial. Eur
Heart J. 2015; 36: 2070–2078
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reduces LDL-receptor recycling, resulting in a
decrease of LDL-C receptors on the surface of
hepatocytes and an increase of plasma LDL-C.
Inhibition of PCSK9 leads to an increase in
surface LDL-C receptors with subsequent
lowering of plasma levels of LDL-C (Fig. 3) [38].
In an open-label extension study of OSLER-1
(ClinicalTrials.gov #NCT01439880) and
OSLER-2 (ClinicalTrials.gov #NCT01854918)
patients were randomly assigned in a 2:1 ratio
to receive the PCSK9 inhibitor evolocumab
(140 mg every 2 weeks or 420 mg monthly)
plus standard therapy (n = 2976) or standard
therapy alone (n = 1487) [39]. At 1 year,
evolucamab reduced LDL by 61% from a
median 120–48 mg/dl; p\0.001) [39].
Evolucamab was not associated with an
increase in serious adverse events (7.5% vs.
7.5%) although neurocognitive side effects were
more frequent (0.9% vs. 0.3%) [39]. Exploratory
analysis suggested evolucamab was associated
with a reduction in the endpoint of combined
CV events (0.95% vs. 2.18%; HR 0.47; 95% CI
0.28–0.78; p = 0.003) which will be further
assessed in the FOURIER (Further
Cardiovascular Outcomes Research With
PCSK9 Inhibition in Subjects With Elevated
Risk) study (ClinicalTrials.gov #NCT01764633)
[39].
A second PCSK9 inhibitor, alirocumab, was
evaluated in the ODYSSEY LONG TERM study
(ClinicalTrials.gov number #NCT01507831) in
which 2341 patients with LDL cholesterol
[1.8 mmol/l despite maximum tolerated
statin were randomized in 2:1 ratio to
alirocumab (150 mg) or placebo subcutaneous
injection every 2 weeks for 78 weeks [40]. At
week 24, LDL-C in the alirocumab group had
dropped 62% more from baseline than with
placebo (p\0.001); an effect that remained
consistent over 78 weeks [40]. Patients
receiving alirocumab reported higher rates of
myalgia (5.4% vs. 2.9%), neurocognitive events
(1.2% vs. 0.5%), and ophthalmologic events
(2.9% vs. 1.9%) [40]. In exploratory post hoc
analysis, MACE events (CHD death, MI,
ischemic stroke, or unstable angina requiring
hospitalization) were 48% lower with
alirocumab (1.7% vs. 3.3%; HR 0.52; 95% CI
0.31–0.90; nominal p = 0.02), which will be
further assessed in the ongoing 18,000-patient,
5-year ODYSSEY OUTCOMES study
(ClinicalTrials.gov number #NCT01663402)
[40].
Less than one-third of smokers hospitalized
with an acute coronary syndrome remain
abstinent following discharge, but the safety of
varenicline in this setting remained to be
established. The Evaluation of Varenicline in
Smoking Cessation for Patients Post-Acute
Coronary Syndrome (EVITA) study
(ClinicalTrials.gov #NCT00794573)
randomized smokers (C10 cigarettes per day)
with acute coronary syndrome (ACS) to
varenicline or placebo [41]. The primary
endpoint (self-reported cessation at 24 weeks
confirmed by carbon monoxide testing) was
achieved in 47.3% of those receiving
varenicline vs. 32.5% receiving placebo
(p = 0.012; number needed to treat 6.8) [41].
At follow-up, continuous abstinence was
reported in 35.8% vs. 25.8% (p = 0.081) and
rates of C50% reduction in cigarettes were
67.4% vs. 55.6% (p = 0.05) [41]. There was no
significant difference in adverse events except
for a higher incidence of abnormal dreams with
varenicline (15.2% vs. 4.6%) [41].
Blood pressure targets were relaxed in most
recent guidelines [42]. The Systolic Blood
Pressure Intervention Trial (SPRINT)
(ClinicalTrials.gov #NCT01206062) [43]
randomized 9361 patients aged over 50 with
systolic blood pressure C130 mmHg, increased
CV risk, but without diabetes, to a target systolic
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Fig. 3 Catabolism of the LDL particle; the role of PCSK9 and
antibody to PCSK9. a Intracellular cholesterol homeostasis is
modulated by the LDLR pathway. The LDLR is a cell-surface
glycoprotein that is synthesized in the ER and processed in the
Golgi apparatus, and transported to the cell surface. The LDLR
speciﬁcally binds ApoB in LDL particles. The resulting
receptor–ligand complex is then internalized by endocytosis,
which involves the LDLRAP1. PCSK9 binds the LDLR–LDL
complex extracellularly and prevents it from dissociating within
the vesicle, thus targeting the whole complex for degradation in
the lysosomal compartment.bAntibody toPCSK9prevents the
binding of PCSK9 to the LDLR–LDL complex. The acidic
environmentof the internalized vesicle results in thedissociation
of the complex. The receptor is recycled to the cell surface,
whereas the LDL particle is degraded in the lysosomal
compartment. Both LDLR and PCSK9 are transcriptionally
regulated by SREBP. Accumulation of free cholesterol released
by hydrolysis of cholesteryl esters in the core of LDL inactivates
SREBP. LDL, low-density lipoprotein;ApoB, apolipoproteinB;
ER, endoplasmic reticulum; LDLR, LDL receptor; LDLRAP1,
LDL receptor adaptor protein 1; PCSK9, pro-protein conver-
tase subtilisin/kexin type 9; SREBP, sterol regulatory ele-
ment-binding protein. Reproduced with permission from
Hovingh, Davidson and Kastelein, et al. Diagnosis and
treatment of familial hypercholesterolemia. Eur Heart J. 2013;
34: 962–971
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pressure\120 mmHg (intensive treatment) or a
target \140 mmHg (standard treatment) [43].
The population was typical of a hypertensive
population with 28% of patients over 75 years
of age and 28% with CKD [43]. A mean systolic
blood pressure of 121.4 mmHg was reached in
the intensive group (achieved on average with
2.8 medications) and 136.2 mmHg (1.8
medications) and standard groups, respectively
[43]. The study was stopped early at 3.26 years
at which point intensive treatment associated
with a 25% reduction in the primary endpoint
of MI, ACS, stroke, heart failure, or death from
CV causes (1.65 %/year vs. 2.19 %/year; HR
0.75; 95 % CI 0.64–0.89; p\0.001) and a 27 %
reduction in all-cause mortality (3.3% vs. 4.5%;
HR 0.73; 95 % CI 0.60–0.90; p = 0.003) [43].
There was a higher rate of hypotension (2.4%
vs. 1.4%; HR 1.67; p = 0.001), syncope,
electrolyte abnormalities, and acute kidney
injury/failure, but not of falls leading to injury
[43]. The SPRINT results are likely to impact on
subsequent hypertension guidelines.
Diuretics remain important treatment
options in blood pressure guidelines although
they may have adverse effects on blood glucose
and potassium. The Prevention And Treatment
of Hypertension With Algorithm based therapy
3 (PATHWAY 3) (ClinicalTrials.gov
#NCT00797862) randomized 441 patients with
systolic blood pressure[140 mmHg, eligible for
diuretic use and with C1 other component of
metabolic syndrome to therapy with amiloride
alone, to combination amiloride plus
hydrochlorothiazide, or to
hydrochlorothiazide alone [44]. Two-hour
glucose concentrations after an oral glucose
tolerance test, averaged at 12 and 24 weeks (the
primary endpoint), were significantly lower
with amiloride alone than hydrochlorothiazide
alone (-0.55 mmol/l, 95% CI -0.96 to -0.14;
p = 0.0093) and in the combination group
compared to hydrochlorothiazide alone
[-0.42 mmol/l (-0.84 to -0.004); p = 0048]
[44]. Mean home systolic blood pressure was
reduced similarly with single treatments, but
combination therapy led to an additional
3.4 mmHg reduction compared with
hydrochlorothiazide (95% CI 0.9–5.8;
p = 0.007) [44]. Hyperkalemia occurred in
seven (4.8%) amiloride patients compared to
three (2.3%) in the combination group [44]. In
summary, combination therapy appeared to be
a favorable treatment option being neutral for
glucose and potassium but with greater effects
on blood pressure [44].
Lower fasting glucose and HbA1c levels with
ranolazine have been suggested by previous
trials in the setting of coronary disease
[45, 46]. A prospective randomized study
presented at the American Diabetes
Association (ADA) 2015 scientific sessions
(ClinicalTrials.gov #NCT01472185) evaluated
the effect of ranolazine on type 2 diabetics
with a HbA1c of 7–10% (53–86 mmol/mol)
compared with placebo [47]. Ranolazine
compared with placebo was associated with a
greater reduction in the primary end point of
fall in HbA1c from baseline at 24 weeks [mean
difference -0.56% (-6.1 mmol/mol);
p\0.0001] and a greater number of patients
achieved HbA1c\7.0% at week 24 (41.2% vs.
25.6%; p = 0.0004) [47]. Thus, ranolazine may
be of particular benefit in patients with
coronary disease and diabetes.
BIOMARKERS IN ACS
The Biomarkers in Acute Cardiovascular Care
(BACC) study (ClinicalTrials.gov
#NCT02355457) investigated the different
cut-off values for high-sensitivity troponin I
and testing at 1 vs. 3 h for early detection of
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acute MI among 1045 patients presenting with
acute ischemic-type chest pain of whom 184
were ultimately diagnosed with acute MI [48]. A
cut-off of 6 ng/l was found to be optimal rather
than a conventional 99th percentile value for
the assay (27 ng/l) [48]. For rule-out MI, using
the 6 ng/l cut off, there was no difference in
negative predictive values between the 1-h
[NPV 99.7 95% CI (98.6–100.0)] and 3-h
measurements [negative predictive value (NPV)
100.0 95% CI (98.5–100.0)] [48]. For rule in MI
(defined as levels of 6 ng/l rising to at least
12 ng/l) there was no significant difference in
positive predictive at 1 or 3 h [82.8 95% CI
(73.2–90.0) vs. 78.6 95% CI (69.8–85.8)] [48].
The BACC findings are in keeping with other
studies suggesting that an accelerated
high-sensitivity troponin protocol may enable
earlier rule in/rule out of acute MI. Use of
additional early biomarkers may improve
diagnosis further at this early time point and
are under investigation.
ANTIPLATELET THERAPY
The optimal duration of dual antiplatelet
therapy (DAPT) after stenting has been widely
debated. The Dual AntiPlatelet Therapy (DAPT)
study (ClinicalTrials.gov #NCT00977938)
randomized 11,648 subjects who were able to
tolerate initial 12 months of DAPT to an
extended further 18 months of DAPT (total
30 months) vs. DAPT discontinuation (total
12 months) [49]. A comparison of subgroups
with and without MI was presented at the ACC
2015 scientific sessions. Extended DAPT was
associated with reduced in-stent thrombosis
(primary endpoint) in those with MI (0.5% vs.
1.9%; p\0.001) and without MI (0.4% vs. 1.1%,
p\0.001) (interaction p = 0.69), reduced new
MI in both post MI and non-MI subgroups, and
reduced MACCE (co-primary endpoint) in those
with MI (3.9% vs. 6.8%; p\0.001) although
only a trend to reduced MACCE in those
without MI (4.4% vs. 5.3%; p = 0.08;
interaction p = 0.03) [49]. However, extended
DAPT was associated with increased moderate
to severe GUSTO bleeding in both MI (1.9% vs.
0.8%; p = 0.005) and non-MI (2.6% vs. 1.7%;
p = 0.007) patients (interaction p = 0.21) [49].
Long-term DAPT was also explored in
PEGASUS-TIMI 54 trial (Prevention of
Cardiovascular Events in Patients with Prior
Heart Attack Using Ticagrelor Compared to
Placebo on a Background of
Aspirin-Thrombolysis in Myocardial Infarction
54) (ClinicalTrials.gov #NCT01225562) [50].
PEGASUS randomized 21,162 patients with a
history of MI during the previous 1–3 years to
extended standard dose ticagrelor (90 mg bd),
extended low dose (60 mg bd) ticagrelor, or
placebo [50].
At a median of 33 months, both ticagrelor
groups showed a significant reduction in the
incidence of the primary endpoint (CV death,
MI or stroke) compared with placebo (7.85%
standard dose ticagrelor (HR 0.85; 95% CI
0.74–0.96; p= 0.008); 7.77% reduced dose
ticagrelor (HR 0.84; 95% CI 0.74–0.95;
p= 0.004); vs. 9.04% placebo) [50]. TIMI major
bleeding rates were significantly (p\0.001)
increased in both ticagrelor groups compared
with placebo (2.60% standard dose ticagrelor,
2.30% reduced dose ticagrelor vs. 1.06% placebo)
although the incidence of intracranial
hemorrhage or fatal bleeding was similar in all
three groups [50]. Dyspnea was significantly more
frequent with ticagrelor (18.93% standard dose
15.84% low dose vs. 6.38% placebo). Standard
dose compared with low dose ticagrelor led to
numerically higher rates of discontinuation [50].
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The DAPT and PEGASUS trials suggest that
patients at high ischemic risk but low bleeding
risk are most likely to benefit from extended
therapy A ‘DAPT score’ has been developed
from the DAPT study dataset to help identify
patients who may derive net benefit and this, or




The requirement for at least 3–6 months of
DAPT has limited use of drug eluting stents
(DES) in patients at high baseline risk of
bleeding. The BioFreedom stainless-steel stent
incorporates a novel microporous abluminal
surface (Fig. 4) that enables controlled release
of Biolimus A9, with therapeutic concentrations
in local tissue sustained up to 28 days
post-implantation [51]. Previous angiographic
studies have reported similar late loss to
conventional DES while the absence of surface
polymer may facilitate early stent healing and a
shorter course of DAPT [51]. The LEADERS-FREE
trial (ClinicalTrials.gov #NCT01623180)
randomized 2466 patients at high baseline
bleeding risk undergoing PCI to BioFreedom or
a bare metal stent with DAPT discontinuation
after 1 month [52]. At 390 days, BioFreedom
was associated with a 50% reduction in the
primary efficacy endpoint of clinically driven
TLR (5.1% vs. 9.8%; HR 0.50; 95% CI 0.37–0.69;
p\0.001), a 29% reduction in the primary
safety endpoint of CV death, stent thrombosis
or MI (9.4% vs. 12.9%; HR 0.71; 95% CI
0.56–0.91; p = 0.005) (Fig. 5), and a 32%
reduction in secondary endpoint of MI (6.1%
vs. 8.9%; HR 0.68; 95% CI 0.50–0.91; p = 0.01)
[52]. Biofreedom appears a logical stent choice
(rather than bare metal stent or conventional
DES) for patients requiring short-course DAPT
or at increased risk of bleeding requiring early
DAPT discontinuation.
The role of PCI vs. CABG for treatment of left
main coronary disease is the ongoing focus of
several large studies. The Premier of
Randomized Comparison of Bypass Surgery vs.
Angioplasty Using Sirolimus-Eluting Stent in
Patients With Left Main Coronary Artery
Disease (PreCOMBAT) (ClinicalTrials.gov
#NCT00422968) trial examined patients with
left main coronary stenosis receiving PCI
(n = 300) compared to CABG (n = 300) [53]. At
5 years, there was no difference in MACCE
(17.5% PCI vs. 14.3% CABG; HR 1.27; 95% CI
0.84–1.90; p = 0.26) or the composite of death,
MI or stroke (8.4% PCI vs. 9.6% CABG; HR 0.89;
95% CI 0.52–1.52; p = 0.66) [53]. Of note, there
was higher rate of ischemia-driven target vessel
revascularization (TVR) with PCI (11.4% PCI vs.
5.5% CABG; HR 2.11; 95% CI 1.16–3.84;
p = 0.012) and 2 PCI patients developed stent
thrombosis [53]. However, PreCOMBAT used
Fig. 4 BioFreedom stainless-steel stent that incorporates a
novel microporous abluminal surface. Reproduced with
permission from Biosensors
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first-generation DES, which are associated with
higher rates of TVR and late stent thrombosis
than latest-generation stents [54]. Results of
NOBLE (Nordic-Baltic-British Left Main
Revascularization Study) (ClinicalTrials.gov
#NCT01496651) comparing Biomatrix flex
with CABG and EXCEL (Evaluation of XIENCE
Everolimus Eluting Stent vs. Coronary Artery
Bypass Surgery for Effectiveness of Left Main
Revascularization) (ClinicalTrials.gov
#NCT01205776) are expected in later 2016.
While the Thrombus Aspiration during
Percutaneous coronary intervention in Acute
myocardial infarction Study (TAPAS) (Current
Controlled Trials #ISRCTN16716833) suggested
a benefit for routine thrombectomy in primary
PCI, the Thrombus Aspiration in ST-Elevation
Myocardial Infarction in Scandinavia Trial
(TASTE) (ClinicalTrials.gov #NCT01093404)
failed to demonstrate a reduction in death, MI,
or stent thrombosis [3]. Given concerns that
TASTE was underpowered to detect smaller
event rates [55], the large Trial of Routine
Aspiration Thrombectomy with PCI vs. PCI
Alone in Patients with STEMI (TOTAL)
(ClinicalTrials.gov #NCT01149044) was
undertaken in which patients with STEMI
undergoing primary PCI were randomized to
routine thrombectomy (n = 5372) vs. primary
PCI alone (n = 5360) [56]. While, like in TAPAS,
routine thrombectomy was associated with
greater ST segment resolution and less distal
embolization, this did not translate into clinical
benefit [56]. There was no reduction in the
primary outcome (CV death, recurrent MI,
cardiogenic shock or NYHA class IV HF at
180 days) (6.9% vs. 7.0% respectively, HR 0.99;
95% CI 0.85–1.15; p = 0.86) [56], no reduction
in the secondary outcome (primary endpoint
plus stent thrombosis or TVR within 180 days)
(9.9% thrombectomy vs. 9.8% PCI alone, HR
1.00; 95% CI 0.89–1.14; p = 0.95), and no
reduction in CV mortality at 180 days (3.1%
thrombectomy vs. 3.5% PCI alone, HR 0.90;
95% CI 0.73–1.12; p = 0.34) [56]. Although
numerically low, stroke rates were increased in
the thrombectomy compared to PCI alone at
both 30 days (0.7% vs. 0.3% respectively, HR
2.06; 95% CI 1.13–3.75; p = 0.02) and 180 days
(52 (1%) vs. 25 (0.5%) respectively HR 2.08; 95%
CI 1.29–3.35; p = 0.02) [56]. Thus routine
thrombectomy is no longer recommended in
primary PCI, although may have a ‘‘bail out’’
role for selected patients [56].
Fig. 5 Primary efﬁcacy and safety endpoints from the
LEADERS-FREE trial for the Biofreedom drug-coated
stent vs. bare metal stenting. TLR target lesion
revascularization, MI myocardial infarction, ST stent
thrombosis. Reproduced with permission from Biosensors
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DANAMI-3 PRIMULTI (The Third DANish
Study of Optimal Acute Treatment of Patients
with ST-segment Elevation Myocardial
Infarction PRImary PCI in MULTIvessel
Disease) (ClinicalTrials.gov #NCT01960933)
compared complete revascularization (with
staged pressure wire-guided PCI of non-culprit
lesions during index admission) (n = 314) vs.
culprit artery intervention alone (n = 313) [57].
The complete revascularization strategy was
associated with a 44% reduction in the
primary endpoint of death, reinfarction, or
ischemia-driven non-culprit artery
revascularization (13% vs. 22%; HR 0.56; 95%
CI 0.38–0.83; p = 0.004), driven by a 69%
reduction in repeat revascularization (5 vs.
17%; HR 0.31; 95% CI 0.18–0.53; p\0.001) of
which 40% was urgent revascularization [57].
Thus, while complete revascularization should
usually be undertaken, since there was no
difference in death or reinfarction, DANAMI-3
suggests a conservative approach to non-culprit
PCI is reasonable if such PCI appears of high risk
[57].
No-reflow following PCI may be associated
with adverse cardiac outcomes and reduced
myocardial salvage (the final infarct size
indexed to the initial area at risk). No reflow,
if it occurs, is most often observed following
stent deployment. The single Korean center
INNOVATION trial (NCT02324348)
randomized 102 STEMI patients deemed at
higher baseline risk of no-reflow following
initial thrombectomy and/or balloon
angioplasty to deferred stenting at 3–7 days vs.
immediate stenting [58]. Deferred stenting was
associated with less no-reflow or slow-reflow
(6% vs. 29%; p = 0.006), less no reflow (2% vs.
14%; p = 0.052), less intra-procedural
thrombotic events (10% vs. 33%; p = 0.010)
and increased myocardial salvage at 6 months
(19.7% vs. 14.7%; p = 0.027) [58]. The study is
too small to be conclusive but a larger European
deferred stent study is ongoing with results
expected in 2016.
Fully bioresorbable stent scaffolds could offer
potential long-term vascular advantages over
conventional DES although appropriate patient
types and safety are still being evaluated.
ABSORB Japan (ClinicalTrials.gov
#NCT01844284) presented at ESC 2015,
randomized 400 patients undergoing PCI to
the Absorb everolimus-eluting bioresorbable
vascular scaffold or the Xience
everolimus-eluting permanent
cobalt-chromium stent [59]. Absorb was
non-inferior to Xience for the primary
endpoint of target lesion failure [cardiac death,
MI attributable to target vessel, or
ischemia-driven target lesion revascularization
(TLR)] at 12 months (4.2% vs. 3.8%;
p non-inferiority \0.0001) [59]. There was no
difference in the rate of 12-month device
thrombosis (although the study was
underpowered for this endpoint), 12-month
TLR, or 13-month angiographic late lumen
loss [59].
The ABSORB III trial (ClinicalTrials.gov
#NCT01751906) randomized 2008 patients
undergoing PCI to one or two de novo lesions
to Absorb or Xience (in 2:1 fashion) [60]. Absorb
was non-inferior to Xience for the primary
endpoint of target lesion failure at 1 year
(7.8% vs. 6.1%; p non-inferiority = 0.007) with
no difference in individual endpoint
components [60]. Of note, Absorb was
associated with a higher rate of subacute
([24 h to 30 days) device thrombosis (0.9% vs.
0.1%; RR 6.26; 95% CI 0.82–48.04; p = 0.04)
although the relative difference was less at
1 year (1.5% vs. 0.7%; RR 2.08; 95% CI
0.78–5.51; p = 0.13) [60]. Intravascular
imaging is usually recommended to guide
optimal B vs. deployment but a surprisingly
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low use was noted in ABSORB III. The
first-generation Absorb B vs. has relatively
thick struts and device thrombosis was less
prevalent in vessels[2.25 mm. Nevertheless, a
meta-analysis of six trials including ABSORB
Japan and ABSORB III did confirm a small but
significant increase in device thrombosis [61].
Thus, appropriate patient/lesion selection,
careful lesion preparation, optical coherence
tomography to guide sizing ± post dilatation
and extended DAPT (to 2 years) is
recommended minimize risk of device
thrombosis.
Reducing bleeding complications following
PCI is an important goal given the association
of bleeding with adverse clinical outcomes. The
MATRIX (Minimizing Adverse Haemorrhagic
Events By Transradial Access Site And Systemic
Implementation Of Angiox) (ClinicalTrials.gov
#NCT01433627) study randomized 8404
patients with ACS, undergoing urgent
angiography (and 80% with follow-on PCI) to
radial or femoral access [62, 63]. Radial access
was associated with a significant reduction in
non-CABG major bleeding (1.6% vs. 2.3%, RR
0.67; 95% CI 0.49–0.92; p = 0.013), a 14.6%
trend to reduction in the primary endpoint of
MACE (death, MI or stroke; 8.8% vs. 10.3%;
95% CI 0.74–0.99; p = 0.0307 although
not-significant at an a of 0.025) [62] and
significant reductions in secondary endpoints
of all-cause mortality (1.6% vs. 2.2%, RR 0.72;
95% CI 0.53–0.99; p = 0.045) and NACE (net
composite of death, MI, stroke, or major
bleeding; 9.8% vs. 11.7%; HR 0.83; 95% CI
0.73–0.96; p = 0.0092) [62]. Such results
strongly support radial access being preferred
as the default access site. A separate
randomization within the MATRIX study to
bivalirudin vs. unfractionated heparin ± bail
out glycoprotein IIb/IIIa inhibition did not
show any difference in MACE or NACE.
In some patients with poor radial access, the
ulnar artery route, although technically more
challenging, may be a useful alternative to
avoid femoral cannulation. The single-center
Ajmer Ulnar Artery Working Group Study
(AJULAR) presented at ACC2015 randomized
2533 patients undergoing PCI by experienced
operators ([50 ulnar procedures) to ulnar or
radial access [64]. There was no significant
difference in the primary endpoint (composite
MACE, site cross-over, major vascular events
during hospital stay; 14.6% TUA vs. 14.4% TRA
95% CI; p = 0.92), or individual components of
the composite endpoint [64].
ARRHYTHMIA AND DEVICES
Requirement for creation of a subcutaneous
pacemaker pocket and insertion of a
transvenous lead in conventional pacing
systems can be associated with important
complications such as pocket hematoma or
infection, pneumothorax, or hemothorax. The
Micra Transcatheter Pacing System Study
(ClinicalTrials.gov #NCT02004873) evaluated
use of a leadless pacemaker (Fig. 6) implanted
in the right ventricular apex via femoral vein
implantation and secured by small tines in 725
patients (719 successfully implanted) [65]. The
primary safety endpoint (freedom from system
or procedure related major complications) was
achieved in 96% and the primary efficacy
endpoint (percentage of patients with low and
stable pacing capture thresholds at 6 months) in
98.3%—both of which were higher than the
minimum performance goals from
conventional pacing historical control data
[65]. Major complications, which were less
common than in the historical control dataset,
included cardiac perforation or
effusion/tamponade (1.6%), groin site
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complication (0.7%), and pacing issues (0.3%)
but no (0%) dislodgments [65].
Another leadless pacemaker—the Nanostim
LP (St. Jude Medical)—was evaluated among
300 patients in the LEADLESS II study
(ClinicalTrials.gov #NCT02030418) [66]. The
primary safety endpoint (6-month freedom
from device-related serious adverse events) was
met in 93.3% and primary efficacy endpoint
(acceptable 6-month pacing threshold and
sensing amplitude) was met in 90%—both also
exceeding minimum performance goals from
conventional pacing historical control data
[66]. In total, 6.7% had serious adverse events
(1.7% device dislodgement with percutaneous
retrieval, 1.3% cardiac perforation and 1.3%
pacing-threshold elevation requiring
percutaneous retrieval and device replacement)
[66]. As each of the leadless pacemaker studies
are observational, larger randomized studies
with longer term data including safety and
retrieval data is required.
AF is present in 30–50% of patients
presenting for mitral valve surgery. Current
guidelines suggest it is reasonable to perform
AF ablation in selected patients undergoing
cardiac surgery but acknowledge that
supporting data are limited. Thus, in a
Cardiothoracic Surgical Trials Network (CTSN)
study (ClinicalTrials.gov #NCT00903370) 260
patients with persistent including longstanding
persistent AF requiring mitral valve surgery were
randomized to ablation or no-ablation groups
[67]. Patients assigned to ablation were further
randomized to pulmonary vein isolation (PVI)
or the more complex biatrial maze. Those
receiving concomitant AF ablation were over
twice as likely to be free from AF on 72-h Holter
at both 6 and 12 months (63.2% vs. 29.4%;
p\0.001) although there no difference whether
performed by PVI or biatrial maze (61% vs. 66%;
p = 0.6) [67]. Ablation was associated with
increased need for permanent pacemaker
implantation (21.5 vs. 8.1 per 100
patient-years, p = 0.01) [67]. There was no
difference in major cardiac or cerebrovascular
adverse events at 12 months but the study was
not powered to show benefit in this respect.
Although the CTSN study did not find an
advantage for the more complex biatrial maze
over PVI, with a transcatheter approach,
persistent AF may benefit more extensive
ablation. The BELIEF trial (ClinicalTrials.gov
#NCT01362738) randomized 173 patients with
long-standing persistent AF undergoing
pulmonary vein antrum and non-pulmonary
vein trigger ablation to additional left atrial
appendage (LAA) electrical isolation (n = 85) or
no LAA isolation (n = 88) [68]. Those
undergoing LAA electrical isolation had
significantly higher freedom from AF at 1-year
(56% vs. 28%; HR, 1.92; p = 0.001) [68]. There
was no significant difference in secondary
endpoints including mortality, stroke, or
re-hospitalization [68].
Anticoagulation strategy was assessed in the
randomized ActiVe-controlled multi-cENTer
Fig. 6 Traditional pacemaker vs. Micra. Reproduced with
permission of Medtronic, Inc
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stUdy with blind-adjudication designed to
evaluate the safety of uninterrupted
Rivaroxaban and uninterrupted vitamin K
antagonists [VKA] in subjects undergoing
cathEter ablation for non-valvular atrial
fibrillation (VENTURE-AF; ClinicalTrials.gov
#NCT01729871, n = 248 patients) [69]. No
adverse safety endpoints were reported for
rivaroxaban and only rarely for VKA (major
bleeding 0.4%; composite of stroke/systemic
embolism/MI/vascular death/bleeding 0.8%)
[69]. While the trial was too small to assess
superiority, it suggests rivaroxaban is a
reasonable alternative to vitamin K antagonists
in patients undergoing catheter ablation in the
setting of uninterrupted anticoagulation [69].
The LEGACY Study (Long-Term Effect of
Goal directed weight management on AF
cohort: a 5-year follow-up study)
(ACTRN12614001123639) evaluated the
long-term impact of weight loss and weight
fluctuation on rhythm control in obese
individuals with symptomatic paroxysmal or
persistent AF [70]. All patients received weight
loss counseling with optional participation in a
weight management clinic or self-managed
program [70]. Those achieving C10% vs.\10%
weight loss had reduced AF burden and
symptom severity (p\0.001) and a sixfold
greater likelihood of arrhythmia-free survival
(p\0.001) irrespective of rhythm control
strategy [70]. Multivariate analyses found
weight loss and weight fluctuation to be
independent predictors of outcomes
(p\0.001) [70].
Outcomes following out of hospital cardiac
arrest remain poor. The Trial of Continuous or
Interrupted Chest Compressions during CPR
conducted by the Resuscitation Outcomes
Consortium) (ClinicalTrials.gov
#NCT01372748) assessed whether outcomes
with non-trauma related cardiac arrest after
continuous compressions with
positive-pressure ventilation (intervention
group) differed from those after compressions
that were interrupted for ventilations at a ratio
of 30 compressions to two ventilations (control
group) [71]. However, there was no significant
difference in survival to hospital discharge
(8.9% vs. 9.7%, 95% CI -1.5 to 0.1; p = 0.07)
or recovery of favorable neurologic function at
discharge (7.0% vs. 7.7%, 95% CI -1.4 to 0.1;
p = 0.09) [71].
IMAGING
The Prospective Multicenter Imaging Study for
Evaluation of Chest Pain (PROMISE) study
(ClinicalTrials.gov #NCT01174550)
randomized 10,003 symptomatic patients to a
strategy of initial anatomical testing with the
use of coronary computed tomographic
angiography (CTA) or to functional testing
(nuclear stress testing 68%, stress
echocardiography 22% or exercise
electrocardiography 10%) [72]. Median
cumulative radiation exposure per patient was
lower with CTA (driven by significantly higher
exposure with nuclear imaging vs. CTA) [72].
Those assigned to CTA vs. functional testing
were more likely to undergo cardiac
catheterization (12.2% vs. 8.1%) but of these,
most patients in the CTA group (72.1%) had
obstructive coronary disease, whereas less than
half in the functional group (47.5%) had
obstructive coronary disease) [72].
Revascularization \90 days was undertaken in
6.2% of the CTA group vs. 3.2% in the
functional group (p\0.001), including 72
patients and 38 patients, respectively, who
underwent CABG [72]. Over a median
follow-up of 25 months there was no
difference in the incidence of the primary
end-point (death, MI, hospitalization for
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unstable angina, or major procedural
complication; 3.3% vs. 3.0%; adjusted HR
1.04; 95% CI 0.83–1.29; p = 0.75) [72]. Thus,
CTA appears to identify coronary disease more
accurately than functional testing although the
clinical impact in PROMISE was unclear.
A second large multicenter CTA study (The
SCOT-HEART trial) has helped to define the
clinical impact of CTA further. SCOT-HEART
randomized 9849 patients with an initial clinical
diagnosis of coronary heart disease (CHD) in
47% and angina due to CHD in 36% to usual
care plus CTA at*6 weeks or to usual care alone
(ClinicalTrials.gov #NCT01149590) [73]. Use of
CTA reclassified diagnosis of CHD in 27% and
angina in 23% (vs. 1% and 1%, respectively, with
usual care p\0.0001) and led to a change in
planned investigation in 15% (cancellation of
121 functional tests, cancellation of 29 invasive
angiograms, but scheduling of an additional 94
invasive angiograms, 88% of which showed
obstructive disease requiring revascularization)
[73]. At a median follow-up of 1.7 years, there
was a 38% trend to reduction in fatal and
non-fatal MI (26 vs. 42, HR 0.62, 95% CI
0.38–1.01; p = 0.0527) [73]. SCOT-HEART thus
confirmed that CTA helps clarify diagnosis,
enables more appropriate use of invasive
angiography/intervention and may reduce the
future risk of MI [73].
CONCLUSIONS
In this paper, we have highlighted and
summarized numerous important studies in
the field of cardiology that have been
presented to major international cardiology
meetings throughout 2015. Many of these
studies will contribute to updating of current
practice guidelines and others will play an
integral role in the advancement and
development of new therapeutic strategies.
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